141 related articles for article (PubMed ID: 35906610)
41. A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer.
Zuo S; Wei M; Zhang H; Chen A; Wu J; Wei J; Dong J
J Transl Med; 2019 May; 17(1):152. PubMed ID: 31088477
[TBL] [Abstract][Full Text] [Related]
42. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
von Pawel J; Spigel DR; Ervin T; Losonczy G; Barlesi F; Juhász E; Anderson M; McCall B; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Reck M
Oncologist; 2018 Jun; 23(6):654-e58. PubMed ID: 29438092
[TBL] [Abstract][Full Text] [Related]
43. Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts.
Rolff J; Becker M; Merk J; Hoffmann J; Fichtner I
Target Oncol; 2016 Aug; 11(4):507-14. PubMed ID: 26817645
[TBL] [Abstract][Full Text] [Related]
44. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
[TBL] [Abstract][Full Text] [Related]
45. EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
Baty F; Rothschild S; Früh M; Betticher D; Dröge C; Cathomas R; Rauch D; Gautschi O; Bubendorf L; Crowe S; Zappa F; Pless M; Brutsche M;
PLoS One; 2013; 8(9):e72966. PubMed ID: 24039832
[TBL] [Abstract][Full Text] [Related]
46. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
Dong M; Yang Z; Li X; Zhang Z; Yin A
Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
[TBL] [Abstract][Full Text] [Related]
47. Epigenetic Suppression of the T-box Subfamily 2 (
Nehme E; Rahal Z; Sinjab A; Khalil A; Chami H; Nemer G; Kadara H
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866410
[TBL] [Abstract][Full Text] [Related]
48. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
[TBL] [Abstract][Full Text] [Related]
49. A 5-Gene Signature Is Closely Related to Tumor Immune Microenvironment and Predicts the Prognosis of Patients with Non-Small Cell Lung Cancer.
Li J; Wang H; Li Z; Zhang C; Zhang C; Li C; Yu H; Wang H
Biomed Res Int; 2020; 2020():2147397. PubMed ID: 31998783
[TBL] [Abstract][Full Text] [Related]
50. Adverse cardiovascular events predict survival benefit in non-small lung cancer patients treated with bevacizumab.
Koyama N
Cancer Biomark; 2014; 14(4):259-65. PubMed ID: 24934369
[TBL] [Abstract][Full Text] [Related]
51. Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
Galván-Femenía I; Guindo M; Duran X; Calabuig-Fariñas S; Mercader JM; Ramirez JL; Rosell R; Torrents D; Carreras A; Kohno T; Jantus-Lewintre E; Camps C; Perucho M; Sumoy L; Yokota J; de Cid R
Cancer Treat Res Commun; 2018; 15():21-31. PubMed ID: 30207284
[TBL] [Abstract][Full Text] [Related]
52. Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer.
Brena RM; Morrison C; Liyanarachchi S; Jarjoura D; Davuluri RV; Otterson GA; Reisman D; Glaros S; Rush LJ; Plass C
PLoS Med; 2007 Mar; 4(3):e108. PubMed ID: 17388669
[TBL] [Abstract][Full Text] [Related]
53. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients.
Tang H; Xiao G; Behrens C; Schiller J; Allen J; Chow CW; Suraokar M; Corvalan A; Mao J; White MA; Wistuba II; Minna JD; Xie Y
Clin Cancer Res; 2013 Mar; 19(6):1577-86. PubMed ID: 23357979
[TBL] [Abstract][Full Text] [Related]
54. Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts.
Vizoso M; Puig M; Carmona FJ; Maqueda M; Velásquez A; Gómez A; Labernadie A; Lugo R; Gabasa M; Rigat-Brugarolas LG; Trepat X; Ramírez J; Moran S; Vidal E; Reguart N; Perera A; Esteller M; Alcaraz J
Carcinogenesis; 2015 Dec; 36(12):1453-63. PubMed ID: 26449251
[TBL] [Abstract][Full Text] [Related]
55. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H; Fukuhara T; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Gemma A; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M
Lancet Oncol; 2019 May; 20(5):625-635. PubMed ID: 30975627
[TBL] [Abstract][Full Text] [Related]
56. Glutathione S-transferase PI (GST-PI) mRNA expression and DNA methylation is involved in the pathogenesis and prognosis of NSCLC.
Grimminger PP; Maus MK; Schneider PM; Metzger R; Hölscher AH; Sugita H; Danenberg PV; Alakus H; Brabender J
Lung Cancer; 2012 Oct; 78(1):87-91. PubMed ID: 22884253
[TBL] [Abstract][Full Text] [Related]
57. (99m)Tc-3P-RGD2 SPECT to monitor early response to bevacizumab therapy in patients with advanced non-small cell lung cancer.
Chen B; Zhao G; Ma Q; Ji B; Ji T; Xin H; Gao S
Int J Clin Exp Pathol; 2015; 8(12):16064-72. PubMed ID: 26884883
[TBL] [Abstract][Full Text] [Related]
58. N-6 methylation-related lncRNA is potential signature in lung adenocarcinoma and influences tumor microenvironment.
Zheng J; Zhao Z; Wan J; Guo M; Wang Y; Yang Z; Li Z; Ming L; Qin Z
J Clin Lab Anal; 2021 Nov; 35(11):e23951. PubMed ID: 34558724
[TBL] [Abstract][Full Text] [Related]
59. The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer.
Shen Z; Chen C; Sun J; Huang J; Liu S
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2239-2248. PubMed ID: 34037837
[TBL] [Abstract][Full Text] [Related]
60. Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer.
Van Laar RK
BMC Med Genomics; 2012 Jul; 5():30. PubMed ID: 22748043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
